文献速递冠心病血脂与心血管预防

不确定潜能克隆性造血预测动脉粥样硬化性心血管疾病患者不良结局

Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该研究基于英国生物银行40至70岁已确诊ASCVD且拥有全外显子测序数据的个体,分析不确定潜能克隆性造血(CHIP)与不良结局的关联。中位随访10.8年,任何CHIP和大克隆CHIP均与主要复合终点独立相关,TET2和剪接体基因CHIP风险最高。

要点

  • 已确诊ASCVD患者中,CHIP独立预测ASCVD事件与全因死亡复合终点。
  • 大克隆CHIP及TET2、剪接体基因CHIP与不良结局关联更强。
  • CHIP或可作为ASCVD患者风险分层的新标志物。

核心结论

  • 在已确诊ASCVD的个体中,CHIP与不良结局独立相关。
  • TET2和SF3B1/SRSF2/U2AF1(剪接体基因)CHIP尤其与大克隆相关风险最高。

研究设计与样本

  • 研究纳入英国生物银行40至70岁、已确诊ASCVD且有全外显子测序数据的个体。
  • 共分析13,129名个体,中位年龄63岁,其中665名(5.1%)存在CHIP。
  • 主要终点为ASCVD事件与全因死亡的复合终点。
  • 采用未校正和多变量校正Cox回归比较CHIP与结局的关联。

主要发现

  • 中位随访10.8年,基线任何CHIP(变异等位基因分数≥2%)与主要终点的校正HR为1.23(95%CI:1.10-1.38;P<0.001)。
  • 基线大克隆CHIP(变异等位基因分数≥10%)与主要终点的校正HR为1.34(95%CI:1.17-1.53;P<0.001)。
  • 大克隆TET2 CHIP与不良结局的HR为1.89(95%CI:1.40-2.55;P<0.001)。
  • 大克隆剪接体CHIP与不良结局的HR为3.02(95%CI:1.95-4.70;P<0.001)。

临床怎么用

  • 对已确诊ASCVD患者,可关注CHIP状态以辅助识别不良结局高风险个体。
  • 尤其应重视大克隆CHIP及TET2、剪接体基因CHIP携带者的风险评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP)-the age-related clonal expansion of blood stem cells with leukemia-associated mutations-is a novel cardiovascular risk factor. Whether CHIP remains prognostic in individuals with established atherosclerotic cardiovascular disease (ASCVD) is less clear. OBJECTIVES: This study tested whether CHIP predicts adverse outcomes in individuals with established ASCVD. METHODS: Individuals aged 40 to 70 years from the UK Biobank with established ASCVD and available whole-exome sequences were analyzed. The primary outcome was a composite of ASCVD events and all-cause mortality. Associations of any CHIP (variant allele fraction ≥2%), large CHIP clones (variant allele fraction ≥10%), and the most commonly mutated driver genes (DNMT3A, TET2, ASXL1, JAK2, PPM1D/TP53 [DNA damage repair genes], and SF3B1/SRSF2/U2AF1 [spliceosome genes]) with incident outcomes were compared using unadjusted and multivariable-adjusted Cox regression. RESULTS: Of 13,129 individuals (median age: 63 years) included, 665 (5.1%) had CHIP. Over a median follow-up of 10.8 years, any CHIP and large CHIP at baseline were associated with adjusted HRs of 1.23 (95% CI: 1.10-1.38; P < 0.001) and 1.34 (95% CI: 1.17-1.53; P < 0.001), respectively, for the primary outcome. TET2 and spliceosome CHIP, especially large clones, were most strongly associated with adverse outcomes (large TET2 CHIP: HR: 1.89; 95% CI: 1.40-2.55; P <0.001; large spliceosome CHIP: HR: 3.02; 95% CI: 1.95-4.70; P < 0.001). CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Gumuser ED, Schuermans A, Cho SMJ, et al. Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2023. PMID: 37197843. doi:10.1016/j.jacc.2023.03.401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。